CRISPR-Cas9 for Drug Discovery in Oncology

被引：2

作者：

Guichard, Sylvie M. ^{[1
]}

机构：

[1] AstraZeneca Pharmaceut LP, IMED Biotech Unit, Waltham, MA 02451 USA

来源：

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 50: PLATFORM TECHNOLOGIES IN DRUG DISCOVERY AND VALIDATION | 2017年 / 50卷

关键词：

GENOMIC REGIONS; HUMAN-CELLS; CANCER; TARGET; CRISPR/CAS9; GENERATION; CAS9; ACTIVATION; KNOCKOUT; PROTEIN;

D O I：

10.1016/bs.armc.2017.08.006

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：61 / 85

页数：25

共 105 条

[1] ENU mutagenesis, a way forward to understand gene function [J].

Acevedo-Arozena, Abraham ;

Wells, Sara ;

Potter, Paul ;

Kelly, Michelle ;

Cox, Roger D. ;

Brown, Steve D. M. .

ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, 2008, 9 :49-69

[2] Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland [J].

Annunziato, Stefano ;

Kas, Sjors M. ;

Nethe, Micha ;

Yucel, Hatice ;

Del Bravo, Jessica ;

Pritchard, Colin ;

Bin Ali, Rahmen ;

van Gerwen, Bas ;

Siteur, Bjorn ;

Drenth, Anne Paulien ;

Schut, Eva ;

van de Ven, Marieke ;

Boelens, Mirjam C. ;

Klarenbeek, Sjoerd ;

Huijbers, Ivo J. ;

van Miltenburg, Martine H. ;

Jonkers, Jos .

GENES & DEVELOPMENT, 2016, 30 (12) :1470-1480

[3]

[Anonymous], 2015, NAT METHODS

[4] Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation [J].

Braun, Christian J. ;

Bruno, Peter M. ;

Horlbeck, Max A. ;

Gilbert, Luke A. ;

Weissman, Jonathan S. ;

Hemann, Michael T. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (27) :E3892-E3900

[5]

Cameron P, 2017, NAT METHODS, V14, P600, DOI [10.1038/nmeth.4284, 10.1038/NMETH.4284]

[6] Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system [J].

Cheng, Albert W. ;

Wang, Haoyi ;

Yang, Hui ;

Shi, Linyu ;

Katz, Yarden ;

Theunissen, Thorold W. ;

Rangarajan, Sudharshan ;

Shivalila, Chikdu S. ;

Dadon, Daniel B. ;

Jaenisch, Rudolf .

CELL RESEARCH, 2013, 23 (10) :1163-1171

[7] Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing [J].

Chiou, Shin-Heng ;

Winters, Ian P. ;

Wang, Jing ;

Naranjo, Santiago ;

Dudgeon, Crissy ;

Tamburini, Fiona B. ;

Brady, Jennifer J. ;

Yang, Dian ;

Gruener, Barbara M. ;

Chuang, Chen-Hua ;

Caswell, Deborah R. ;

Zeng, Hong ;

Chu, Pauline ;

Kim, Grace E. ;

Carpizo, Darren R. ;

Kim, Seung K. ;

Winslow, Monte M. .

GENES & DEVELOPMENT, 2015, 29 (14) :1576-1585

[8] CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A [J].

Chu, Jennifer ;

Galicia-Vazquez, Gabriela ;

Cencic, Regina ;

Mills, John R. ;

Katigbak, Alexandra ;

Porco, John A., Jr. ;

Pelletier, Jerry .

CELL REPORTS, 2016, 15 (11) :2340-2347

[9] In Silico Meets In Vivo: Towarcs Computational CRISPR-Based sgRNA Design [J].

Chuai, Guo-hui ;

Wang, Qi-Long ;

Liu, Qi .

TRENDS IN BIOTECHNOLOGY, 2017, 35 (01) :12-21

[10] Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework [J].

Cook, David ;

Brown, Dearg ;

Alexander, Robert ;

March, Ruth ;

Morgan, Paul ;

Satterthwaite, Gemma ;

Pangalos, Menelas N. .

NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (06) :419-431

← 1 2 3 4 5 6 7 8 9 10 →